The Company allocates goodwill to reporting units within its Mobile Solutions, Industrial Solutions and Life Sciences segments. There were no dispositions or impairment charges recorded during the years ended July 31, 2026, 2025 and 2024. Goodwill is assessed for impairment annually during the third quarter of the fiscal year, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2026 and did not record any impairment as a result of this assessment.


	Mobile Solutions Segment		Industrial Solutions Segment		Life Sciences Segment		Total Goodwill
Balance as of July 31, 2024	$	25.4	$	289.9	$	163.1	$	478.4
Goodwill acquired	—		3.2		—		3.2

Foreign exchange translation	—		5.1		6.9		12.0
Balance as of July 31, 2025	$	25.4	$	298.2	$	170.0	$	493.6
Goodwill acquired	—		587.4		—		587.4
Foreign exchange translation	0.3		5.1		0.4		5.8
Balance as of July 31, 2026	$	25.7	$	890.7	$	170.4	$	1,086.8

During the fourth quarter of fiscal year 2026, $587.4 million of goodwill within the Industrial Solutions segment was acquired through the acquisition of Facet. The Company believes the goodwill balance associated with the business combination is primarily attributed to the benefit of access to durable, growing end markets and recurring, regulated replacement part sales with accretive margins. See Note 2 for additional information.


	Year Ended July 31, 2026
	Weighted Amortizable Life (in Years)	Gross Carrying Amount		Accumulated Amortization		Net
Customer relationships	12.1	$	265.0	$	(50.5)	$	214.5

Trademarks	9.5	23.2		(3.2)		20.0
Technology and patents	15.8	81.5		(22.2)		59.3
Non-compete agreements	3.2	1.2		(0.8)		0.4
Other	5.5	16.1		(5.7)		10.4
Total intangible assets		$	387.0	$	(82.4)	$	304.6


	Year Ended July 31, 2025
	Weighted Amortizable Life (in Years)	Gross Carrying Amount		Accumulated Amortization		Net
Customer relationships	8.5	$	74.7	$	(43.7)	$	31.0

Trademarks	6.7	3.8		(2.0)		1.8
Technology and patents	16.6	82.9		(19.1)		63.8
Non-compete agreements	2.9	2.5		(1.7)		0.8
Total intangible assets		$	163.9	$	(66.5)	$	97.4

In connection with the acquisition of Facet during fiscal 2026, the Company recorded intangible assets with an aggregate fair value of $225.6 million, consisting of customer relationships totaling $191.3 million with a 13 year useful life, trademarks totaling $19.1 million with a 10 year useful life and other intangibles totaling $15.2 million with useful lives ranging from 15 months to 10 years. See Note 2 for additional information.

In the third quarter of fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. Estimates and assumptions are utilized in the valuations, including discounted projected cash flows, earnings before interest, taxes, depreciation and amortization margins, terminal value growth rates, revenue growth rates, discount rates and the determination of comparable publicly traded companies. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing businesses within the Life Sciences segment, including $53.1 million of impairment expense related to technology and patents, $7.7 million of impairment expense related to trademarks, $1.0 million of impairment expense related to customer relationships and $0.2 million of impairment expense related to non-compete agreements. The impairment expense was included in loss on impairment of intangible assets in the Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined.